Proposal and Validation of the Minimum Clinically Important Difference in Emphysema Progression.

Area of Science:

• Pulmonary Medicine
• Radiology
• Genetics

Background:

• Emphysema severity is assessed using lung density on computed tomography (CT) scans.
• In alpha-1 antitrypsin deficiency (AATD), lung density changes are primary outcomes in disease-modifying therapy trials.
• The minimum clinically important difference (MCID) for lung density change in AATD is currently unknown.

Purpose of the Study:

• To derive and validate MCIDs for lung density values in patients with AATD.
• To establish a clinically meaningful threshold for changes in lung density observed via CT scans.
• To inform the design and interpretation of clinical trials for emphysema in AATD.

Main Methods:

• Employed distribution and anchoring methods using forced expiratory volume in 1 second (FEV1) to derive MCIDs for lung density.
• Utilized data from systematic reviews on CT density measurements and AATD therapies to analyze absolute and annual lung density changes.
• Validated derived MCID values against mortality, lung function, and health status in a UK AATD cohort using regression analysis.

Main Results:

• Anchor and distribution methods yielded a probable annual MCID of -1.87 g/L/year (range -1.53 to -2.20).
• Absolute lung density change showed a probable MCID of -2.04 g/L (range -1.83 to -2.30).
• A significant difference in lung function (p<0.001) and increased mortality risk (p<0.05) were observed in individuals with absolute lung density loss exceeding -2.04 g/L.

Conclusions:

• Absolute lung density change, with an established MCID of -2.04 g/L, is a potential outcome measure for emphysema-modifying therapies in AATD.
• This finding suggests that absolute lung density change is a more sensitive outcome than annual density change for evaluating treatment efficacy.
• The derived MCID provides a benchmark for assessing the clinical importance of treatment effects in AATD clinical trials.